Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Cash from Financing Activities (2016 - 2025)

Amicus Therapeutics filings provide 16 years of Cash from Financing Activities readings, the most recent being $14.0 million for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities rose 1178.85% to $14.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $610000.0, a 88.09% decrease, with the full-year FY2025 number at $610000.0, down 88.09% from a year prior.
  • Cash from Financing Activities hit $14.0 million in Q4 2025 for Amicus Therapeutics, up from -$1.3 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $201.1 million in Q3 2021 to a low of -$13.3 million in Q1 2024.
  • Median Cash from Financing Activities over the past 5 years was $625000.0 (2022), compared with a mean of $13.6 million.
  • Biggest five-year swings in Cash from Financing Activities: crashed 192.35% in 2022 and later skyrocketed 6829.7% in 2023.
  • Amicus Therapeutics' Cash from Financing Activities stood at -$104000.0 in 2021, then soared by 635.58% to $557000.0 in 2022, then soared by 1373.97% to $8.2 million in 2023, then plummeted by 86.64% to $1.1 million in 2024, then skyrocketed by 1178.85% to $14.0 million in 2025.
  • The last three reported values for Cash from Financing Activities were $14.0 million (Q4 2025), -$1.3 million (Q3 2025), and -$400000.0 (Q2 2025) per Business Quant data.